Skip to Main Content

Office of Mental Health


Cardiometabolic Risk

The PSYCKES Cardiometabolic Risk quality indicators focus on the risks that antipsychotic medications can pose to the health of consumers who have pre-existing health conditions that put them at risk for heart attacks, peripheral vascular disease, or strokes. The National Association of State Mental Health Program Directors (NASMHPD) noted in a 2006 report that consumers with serious mental illness die, on average, 25 years earlier than the general population. The major cause of this increased mortality was cardiovascular disease. The cardiometabolic quality indicators developed by PSYCKES identify consumers who have at least one risk factor for or already have cardiovascular disease, and who are currently prescribed an antipsychotic with a high or moderate risk of side effects such as diabetes, weight gain, and high cholesterol.

The Cardiometabolic Risk Reference Guide (360kb) provides:

  • brief definitions of each indicator within the Cardiometabolic Risk indicator set,
  • a summary of the scientific evidence regarding cardiometabolic risk
  • clinical recommendations for reducing cardiometabolic risk, and
  • an annotated bibliography of key scientific articles.

Detailed information about the Cardiometabolic Risk indicators can be found in the Technical Specifications (335kb).

For QI teams wishing to identify cardiometabolic risk outside of the Medicaid population, chart review forms are available. The Psychotropic Medication Reference Table (386kb) provides information on how medications are classified.

OMH has developed several educational resources about cardiometabolic risk, including:

Comments or questions about the information on this page can be directed to the PSYCKES Team.